Agenus (AGEN) to Release Earnings on Tuesday

Agenus (NASDAQ:AGEN) is set to post its quarterly earnings results before the market opens on Tuesday, November 12th. Analysts expect Agenus to post earnings of ($2.30) per share for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.

Agenus (NASDAQ:AGEN) last posted its earnings results on Thursday, August 8th. The biotechnology company reported ($2.52) EPS for the quarter, missing analysts’ consensus estimates of ($1.33) by ($1.19). The business had revenue of $23.51 million for the quarter, compared to analyst estimates of $64.73 million. During the same period in the previous year, the business posted ($4.00) earnings per share. On average, analysts expect Agenus to post $-11 EPS for the current fiscal year and $-11 EPS for the next fiscal year.

Agenus Trading Down 0.8 %

Shares of AGEN opened at $3.90 on Monday. The firm has a market cap of $84.12 million, a PE ratio of -0.34 and a beta of 1.39. Agenus has a 1-year low of $3.75 and a 1-year high of $19.69. The firm has a fifty day simple moving average of $4.89 and a two-hundred day simple moving average of $8.94.

Analysts Set New Price Targets

Several research analysts have issued reports on AGEN shares. Robert W. Baird cut Agenus from an “outperform” rating to a “neutral” rating and dropped their target price for the stock from $35.00 to $8.00 in a research report on Friday, July 19th. StockNews.com lowered shares of Agenus from a “hold” rating to a “sell” rating in a research report on Monday, August 12th. Jefferies Financial Group reiterated a “hold” rating and issued a $7.00 price target (up from $3.00) on shares of Agenus in a research report on Friday, July 19th. Baird R W downgraded shares of Agenus from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 19th. Finally, William Blair cut Agenus from an “outperform” rating to a “market perform” rating in a report on Thursday, July 18th. One analyst has rated the stock with a sell rating, five have given a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $10.50.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.